Tamoxifen has been the mainstay of adjuvant drug treatment aimed at reducing the risk of recurrence of breast cancer. Yet, in light of new information about the utility of aromatase inhibitors as adjuvant therapy, such as that provided by the Arimidex, Tamoxifen, Alone or in Combination (ATAC) study, oncologists may have more options. Early indications are that, in comparison with tamoxifen, aromatase inhibitors increase disease-free survival for postmenopausal women with hormone receptor-positive early-stage breast cancer.
Breast Cancer: An Overview of the Disease
Advances in Systemic Treatment of Early Breast Cancer in Postmenopausal Women
Managing Treatment of Early Breast Cancer in Postmenopausal Patients: A Nurse Practitionerís View
A Medical Directorís Perspective on Early Breast Cancer